If you follow aging science—and my guess is that you’re one of those mortal, aging types who do—you might want to take a look at the latest issue of Scientific American (the January 2012 issue), which has a cover story I wrote for the magazine about research on target of rapamycin (TOR) and its implications for aging and finding ways to slow it down. Accompanying the article is a blog I wrote about how politics and faulty perceptions are preventing the huge practical promise of aging research from being realized, and why we should change that ASAP. There’s also a slide show about the very different rates of aging (and longevity) across mammals, and a piece on the extraordinary longevity of naked mole-rats, an adaptation of part of my book’s chapter on aging across species.
Scientific American on TOR and Aging
If you follow aging science—and my guess is that you’re one of those mortal, aging types who do—you might want to take a look at the latest issue of Scientific American (the January 2012 issue), which has a cover story I wrote for the magazine about research on target of rapamycin (TOR) and its implications for aging and finding ways to slow it down. Accompanying the article is a blog I wrote about how politics and faulty perceptions are preventing the huge practical promise of aging research from being realized, and why we should change that ASAP. There’s also a slide show about the very different rates of aging (and longevity) across mammals, and a piece on the extraordinary longevity of naked mole-rats, an adaptation of part of my book’s chapter on aging across species.